Literature DB >> 34392660

Traditional Chinese Medicine reverses resistance to epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer: a narrative review.

Jia-Yang Chen1, Li Feng1.   

Abstract

OBJECTIVE: To review mechanisms of the resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of non-small cell lung cancer and the reversal of this resistance by traditional Chinese herbal medicines (CHMs).
METHODS: Searching China National Knowledge Infrastructure Database, Wanfang Database, China Science and Technology Journal Database, PubMed and Embase for related researches
RESULTS: T790M mutation, MET amplification, C797S mutation, Inactivation of PTEN gene expression and Epithelial-mesenchymal transition (EMT) are the main mechanisms of the resistance to EGFR-TKIs. CHMs may reverse the resistance by inhibiting MET activation, inhibiting PI3K/AKT pathways, regulating apoptosis and P-glycoprotein (P-gp).
CONCLUSION: Many resistance mechanisms of EGFR-TKIs in the treatment of non-small cell lung cancer still need to be explored. CHMs have great research potential in reversing the resistance to EGFR-TKIs.

Entities:  

Keywords:  Carcinoma, non-small-cell lung; Drug resistance; ErbB receptor; Herbal medicine

Mesh:

Substances:

Year:  2021        PMID: 34392660     DOI: 10.19852/j.cnki.jtcm.2021.03.017

Source DB:  PubMed          Journal:  J Tradit Chin Med        ISSN: 0255-2922            Impact factor:   0.848


  2 in total

1.  Efficacy and safety of EGFR‑TKIs plus Shenqi Fuzheng injection for non-small cell lung cancer patients with EGFR-sensitive mutations.

Authors:  Jia-Li Wang; Chuan-Sheng Chen; Zhi-Rong Jia; Li-Yun Miao; Jun Xie; Zhen-Zhen Pan; Ya-Lei Duan; Shuo Liu; Meng-Jun Hou; Xuan-Sheng Ding
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-26       Impact factor: 4.322

Review 2.  Current Research on Complementary and Alternative Medicine in the Treatment of Premature Ovarian Failure: An Update Review.

Authors:  Yue Li; Meng-Yu Yan; Qiao-Chu Chen; Ya-Ya Xie; Chen-Yu Li; Feng-Juan Han
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-23       Impact factor: 2.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.